Decentralized and hybrid clinical trials hold significant promise for improving access and reducing patient burden. But implementing them introduces operational, cultural, and trust-related challenges that technology alone cannot solve. In this webinar, Craig Lipset, Liam Eves, and host Paul Wicks explored where decentralized trials break down in practice and what it takes to make them work.
MASH (Metabolic dysfunction-associated steatohepatitis) is a chronic liver disease that has gained significant attention from the pharmaceutical industry and clinical societies in the last decade. In this webinar, Dimitar Tonev, a trained hepatologist and an expert in chronic liver diseases, chatted with Patrick Short, CEO of Sano Genetics, to provide insights into the challenges and opportunities in developing drugs for MASH.
This webinar was hosted by Paul Wicks and featured Sano CEO Patrick Short, Rakhi Rajani from Genomics England, and Julian Hastings Ward who chairs the participant panel for Genomics England.
This webinar, hosted by Patrick Short, CEO of Sano Genetics, and featuring Dr. Mark Kotter, CEO of bit.bio, focused on precision medicine in multiple sclerosis. The conversation ranged from stem cells and the effect they can have on neurodegenerative disease like multiple sclerosis to the future of synthetic biology.
This webinar, hosted by Sano Genetics and featuring representatives from Newcastle University, Congenica, UK CRC Tissue Directory and Co-ordination Centre and Sano Genetics, focussed on the topic of diversity in clinical trials. The speakers discussed how to promote diversity in research participation, the importance of patient engagement and involvement, and how to flag potential issues earlier in the research process.
This webinar was hosted by Sano Genetics' scientific advisor, Paul Wicks, and featured representatives from Genomics England as well as Sage Bionetworks. The discussion centered around experiences and insights on patient engagement in precision medicine research, including how patients can be more involved in this type of research, as well as how design systems can impact engagement.
In this webinar, Patrick Short (Co-Founder and CEO at Sano Genetics) and Will Jones (Co-Founder and CTO at Sano Genetics) discuss the technical challenges of biomarker-based pre-screening. Patrick and Will touch on the importance of running large-scale clinical research programs that are focused on biomarkers, the challenges of finding a central source of truth for participant numbers, how best to ensure compliance across different jurisdictions, and how to engage participants in long-term programs.
Recruitment remains one of the most consequential operational challenges in clinical research. This article examines the structural factors that drive enrollment failure, the shift toward digital and patient-centered methods, and the operational practices that determine whether a trial reaches its target population on time.
Patient experience is far more than a performance metric. It is a structural factor that shapes enrollment, retention, and the long-term quality of clinical research. Understanding what it means, and how to measure and improve it, is essential for teams designing studies that depend on sustained participant engagement.
- Sano raises $11 million in Series A funding round led by MMC Ventures
- New funding will support the team to grow and further its mission to accelerate personalised medicine research
- Sano aims to address the challenge of a decades-long, costly drug development process so that new treatments can reach patients faster